US Food and Drug Administration pushed to change.

The article looks at the U.S. Food and Drug Administration (FDA). According to FDA's acting commissioner Andrew von Eschenbach, the FDA must change the way it examines and approves new drugs and medical devices. The article discusses FDA's failure to act on the application of the morning after emergency contraceptive, the FDA's Critical Path Initiative, legislation in U.S. Congress that would allow more changes in drug-approval process of the FDA, known as the "Access, Compassion, Care, and Ethics for Seriously III Patients Act," and a report by the U.S. Government Accountability Office that criticized the FDA's monitoring of postmarket drug safety.